The burden of brain diseases in Europe
- PMID: 12940825
- DOI: 10.1046/j.1468-1331.2003.00682.x
The burden of brain diseases in Europe
Abstract
The burden [as defined by the World Health Organisation (WHO)] of brain diseases (neurological, neurosurgical and psychiatric diseases together) is very high and yet resources spent on these diseases are not necessarily commensurate with the extent of this burden. However, hard data on the burden of brain diseases in Europe have not previously been easily accessible. The Global Burden of Disease (GBD) 1990 study conducted jointly by the WHO, Harvard University and the World Bank provided new measures that are now becoming universally accepted and have been used also in a repeat study: The GBD 2000. The key parameter of the study is disability adjusted life years (DALY), which is the sum of years of life lost (YLL) caused by premature death and years of life lived with disability (YLD). In the present report, data from the GBD 2000 study and from the World Health Report 2001 on brain diseases is extracted for the territory of Europe. This territory corresponds roughly to the membership countries of the European Federation of Neurological Societies. The WHO's Report has a category called neuropsychiatric diseases, which comprises the majority but not all the brain diseases. In order to gather all brain diseases, stroke, meningitis, half of the burden of injuries and half of the burden of congenital abnormalities are added. Throughout Europe, 23% of the years of healthy life is lost and 50% of YLD are caused by brain diseases. Regarding the key summary measure of lost health, DALY, 35% are because of brain diseases. The fact that approximately one-third of all burden of disease is caused by brain diseases should have an impact on resource allocation to teaching, reasearch, health care and prevention. Although other factors are also of importance, it seems reasonable that one-third of the curriculum at medical school should deal with the brain and that one-third of life science funding should go to basic and clinical neuroscience. In addition, resource allocation to prevention, diagnosis and treatment of brain diseases should be increased to approach, at least, one-third of health care expenditure. With the present data on hand, neurologists, neurosurgeons, psychiatrists, patient organizations and basic neuroscientists have a better possibility to increase the focus on the brain.
Similar articles
-
The state of health in the Arab world, 1990-2010: an analysis of the burden of diseases, injuries, and risk factors.Lancet. 2014 Jan 25;383(9914):309-20. doi: 10.1016/S0140-6736(13)62189-3. Epub 2014 Jan 20. Lancet. 2014. PMID: 24452042
-
Measuring the burden of disease using disability-adjusted life years in Shilin County of Yunnan Province, China.Environ Health Prev Med. 2011 May;16(3):148-54. doi: 10.1007/s12199-010-0176-8. Epub 2010 Sep 4. Environ Health Prev Med. 2011. PMID: 21431803 Free PMC article.
-
[Changing trend regarding the burden on cerebrovascular diseases between 1990 and 2016 in China].Zhonghua Liu Xing Bing Xue Za Zhi. 2019 Apr 10;40(4):400-405. doi: 10.3760/cma.j.issn.0254-6450.2019.04.006. Zhonghua Liu Xing Bing Xue Za Zhi. 2019. PMID: 31006198 Chinese.
-
Mortality landscape in the global burden of diseases, injuries and risk factors study.Eur J Intern Med. 2014 Jan;25(1):1-5. doi: 10.1016/j.ejim.2013.09.002. Epub 2013 Sep 29. Eur J Intern Med. 2014. PMID: 24084027 Review.
-
Global "burden of disease"-study for psychiatric disorders.Psychiatr Prax. 2001 Jul;28 Suppl 1:S7-11. doi: 10.1055/s-2001-15381. Psychiatr Prax. 2001. PMID: 11533901 Review.
Cited by
-
Dietary inflammatory index and brain disorders: a Large Prospective Cohort study.Transl Psychiatry. 2025 Mar 27;15(1):99. doi: 10.1038/s41398-025-03297-4. Transl Psychiatry. 2025. PMID: 40148290 Free PMC article.
-
Nitric Oxide Synthase Inhibitors as Antidepressants.Pharmaceuticals (Basel). 2010 Jan 20;3(1):273-299. doi: 10.3390/ph3010273. Pharmaceuticals (Basel). 2010. PMID: 27713253 Free PMC article. Review.
-
Thinking inside the box. To cope with an increasing disease burden, drug discovery needs biologically relevant and predictive testing systems.EMBO Rep. 2007 Jul;8 Spec No(Suppl 1):S40-3. doi: 10.1038/sj.embor.7400939. EMBO Rep. 2007. PMID: 17726442 Free PMC article. Review. No abstract available.
-
Luminescence Thermometry for Brain Activity Monitoring: A Perspective.Front Chem. 2022 Jul 12;10:941861. doi: 10.3389/fchem.2022.941861. eCollection 2022. Front Chem. 2022. PMID: 35903194 Free PMC article. Review.
-
Cost of disorders of the brain in Italy.Neurol Sci. 2008 Apr;29(2):99-107. doi: 10.1007/s10072-008-0868-7. Epub 2008 May 16. Neurol Sci. 2008. PMID: 18483707
MeSH terms
LinkOut - more resources
Full Text Sources
Medical